Reipu Biotech (300119): Continuing the growth trend, swine and pet vaccines are expected to release elasticity

1Q24 results are in line with our expectations, Ruipu Biotech announced 1Q24 results: the company achieved revenue of 533 million yuan, +20.4% year-on-year, net profit to mother was 88 million yuan, +8.3% year-on-year, deducted from non-return to mother

中金公司Apr 27 15:51

Reipu Biotech (300119.SZ): In the future, it is planned to launch products such as oral insect repellents, cat fever monoclonal antibodies, canine quadruplets, etc.

Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024, to discuss “What is the current channel development situation in the pet sector and the channel side plans for this year? What big products are worth looking forward to?” The company replied that the company has set up nearly 100 core dealers in all provinces and cities across the country, covering major Tier 1 and 2 cities across the country, and has covered more than 5,000 channel stores nationwide. In 2024, the company will continue to optimize dealers and sink channels to prefecture-level markets; form a mutually beneficial and win-win mechanism with core dealers, deepen cooperation and bonds; and strengthen

Gelonghui FinanceApr 26 15:36

Ruipu Biotech (300119.SZ): This year, the company also plans to market a live recombinant H5 vaccine against duck fever, as well as several Chinese veterinary drugs such as bacteriophages and Xubiying extract

Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “What major products will the company launch in the poultry sector in the past two years?” The company replied that in the poultry sector, the company focuses on multivalent multivalent vaccines, original pharmaceutical preparations, Chinese veterinary medicine products, etc. Recently, the company received three new veterinary drug certificates for the triple inactivated vaccine (LaSota strain+TJ-4 strain+RP-8-c strain), and Avian Adenovirus (H9 subtype), and aims to launch it on the market this year. In addition, the company also plans to go public and restructure Duck Fever this year

Gelonghui FinanceApr 26 15:35

Reipu Biotech (300119.SZ): The cat triple vaccine was launched at the end of January this year, with cumulative sales of about 12 million yuan in the first quarter

Gelonghui April 26 | Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “The current promotion status of the triple vaccine for cats?” The company replied that the triple vaccine for cats was launched at the end of January this year, with cumulative sales of about 12 million yuan in the first quarter, and the terminals covered 4,600 pet hospitals. Up to now, there have been no cases of side effects of the triple vaccine for cats. The safety and efficacy have reached the expected level, and it has gradually developed a reputation among pet hospitals and pet owners. During the reporting period, “Rui Meow Shu” was the only officially designated vaccine for the FiFe China Cat Race. It was a professional cat racing cat

Gelonghui FinanceApr 26 15:34

Guohai Securities released a research report on April 26 stating that it gave Ruipu Biotech (300119.SZ) a purchase rating. The main reasons for the rating include: 1) business performance bucking the trend; 2) the successful launch of the cat triple vacci

Guohai Securities released a research report on April 26 stating that it gave Ruipu Biotech (300119.SZ) a purchase rating. The main reasons for the rating include: 1) business performance bucking the trend; 2) the successful launch of the cat triple vaccine, which is expected to achieve import substitution; 3) with the acquisition of Biwei Antai, the livestock vaccine business is expected to grow rapidly. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 26 14:25

Ruipu Biotech (300119): Steady profit growth in Q1, livestock and pet growth can be expected

24Q1 performance grew steadily, and the increase in livestock and pets can be expected. Against the backdrop of challenging livestock and poultry farming, the company's 24Q1 performance increased steadily, achieving a net profit of 88 million yuan to mother, an increase of 8.35% over the previous year. We expect 20

華泰證券Apr 26 00:00